Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 6 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 3 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tumour multifocality offers no risk prognostic value in PTC outcomes

10 Oct 2017

It appears that tumour multifocality does not predict clinical outcomes of papillary thyroid cancer (PTC), suggests a recent study.

“Multifocality is often treated as a risk factor for PTC, prompting aggressive treatments,” according to researchers.

To determine the prognostic value of tumour multifocality in clinical outcomes of PTC, the investigators recruited 2,638 patients (median age 46 years; 2,015 women) and followed them for a median 58 months at 11 medical centres in six countries. The Surveillance, Epidemiology and End Results (SEER) data was used for validation.

Disease recurrence was 198 of 1,000 (19.8 percent) in multifocal and 221 of 1,624 (13.6 percent) in unifocal PTC (hazard ratio [HR], 1.55; 95 percent CI, 1.28 to 1.88; p<0.001). This became insignificant after multivariate adjustment (HR, 1.13; 0.93 to 1.37).

The results were comparable in PTC variants, including conventional PTC, follicular-variant PTC, tall-cell PTC and papillary thyroid microcarcinoma. No association existed between multifocality and mortality in any of these PTC settings. However, classic risk factors strongly predicted cancer recurrence or mortality, and this association remained significant after multivariate adjustment.

In patients with intrathyroidal PTC (n=1,423), disease recurrence was 20 of 455 (4.4 percent) and 41 of 967 (4.2 percent; p=0.892) and mortality was zero of 455 (0.0 percent) and three of 967 (0.3 percent; p=0.556) in multifocal and unifocal PTC, respectively.

“The results were reproduced in 89,680 patients with PTC in the SEER database,” according to researchers.

The indiscriminate use of tumour multifocality as an independent risk factor, prompting overtreatment of patients, should be avoided, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 6 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 3 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.